A randomized, double-blind, multicenter study of visilizumab versus placebo in subjects with intravenous steroid-refractory ulcerative colitis previously responsive in a visilizumab study.
Phase of Trial: Phase II/III
Latest Information Update: 04 Sep 2014
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Abbott Biotherapeutics Corp; PDL BioPharma
- 09 Mar 2012 Actual patient number 25 added as reported by ClinicalTrials.gov.
- 25 Sep 2009 New trial record.